ArticleKidney international2012
Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury.
Article in Kidney international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 66 citations in OpenAlex.
- Review
- Advanced Immunomodulatory Biomaterials for Therapeutic Applications.Advanced healthcare materials · 2025Review
- CD8 + CD103 + iTregs protect against ischemia-reperfusion-induced acute kidney Injury by inhibiting pyroptosis.Apoptosis : an international journal on programmed cell death · 2024Article
- Contribution of Tregs to the promotion of constructive remodeling after decellularized extracellular matrix material implantation.Materials today. Bio · 2024Article
- Unveiling the Renoprotective Mechanisms of Schisandrin B in Ischemia-Reperfusion Injury Through Transcriptomic and Pharmacological Analysis.Drug design, development and therapy · 2024Article
- The role of regulatory T cells in the pathogenesis of acute kidney injury.Journal of cellular and molecular medicine · 2023Article
- Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment.Nature communications · 2023Article
- CD4Frontiers in immunology · 2023Review
- The Mechanism of Delayed Ischemic Preconditioning in Alleviating Acute Ischemia/Reperfusion Renal Injury through Treg Mediated by Immature CD11cKidney diseases (Basel, Switzerland) · 2022Article
- Modulation of the Immune System Promotes Tissue Regeneration.Molecular biotechnology · 2022Review
- Indoleamine 2,3 Dioxygenase 1-The Potential Link between the Innate Immunity and the Ischemia-Reperfusion-Induced Acute Kidney Injury?International journal of molecular sciences · 2022Review
- M2c Macrophages Protect Mice from Adriamycin-Induced Nephropathy by Upregulating CD62L in Tregs.Mediators of inflammation · 2022Article
- Review
- The Dynamic Inflammatory Tissue Microenvironment: Signality and Disease Therapy by Biomaterials.Research (Washington, D.C.) · 2021Review
- The Role of the Immune Microenvironment in Bone Regeneration.International journal of medical sciences · 2021Review
- Large animal models for translational research in acute kidney injury.Renal failure · 2020Review
- Role of chemokines, innate and adaptive immunity.Cellular signalling · 2020Review
- T Cells and Acute Kidney Injury: A Two-Way Relationship.Frontiers in immunology · 2020Review
- Protective effect of bone marrow mesenchymal stem cells modified with klotho on renal ischemia-reperfusion injury.Renal failure · 2019Article
- Epigenetic reprogramming of immune cells in injury, repair, and resolution.The Journal of clinical investigation · 2019Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Regulatory T cells (Tregs) are key components of the peripheral tolerance system and have become an immunotherapeutic agent for treating inflammatory processes. This therapeutic option, however, is hampered by problems arising from isolating and expanding desirable Tregs. Here we used an alternative approach with a pharmacologic agent to stimulate Tregs to achieve immunosuppressive effects. Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury. DMS itself had no effects on renal function or histopathology, but rapidly and transiently increased both Teffs and Tregs and increased the expression of chemokines CXCL9, CCL5, and CXCL10 in non-ischemic kidneys (sham operation). This renoprotection was abolished by administration of the Treg suppressing agents, anti-CTLA-4 or anti-CD25 monoclonal antibodies, suggesting that Tregs play a key role in DMS-induced renoprotection. Thus, Tregs recruited to the kidney by DMS ameliorate acute kidney injury and provide a new approach to control inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.